# US 11,078,269 B2 · IL-11Rα antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,269 B2
- Document ID: US11078269B2
- Status: Granted
- Kind: B2
- Application number: 16/726,190
- Filed: 2019-12-23
- Published: 2020-07-02
- Granted: 2021-08-03
- Earliest claimed: 2016-12-16
- Assignees: Singapore Health Services Pte Ltd; National University of Singapore
- Applicants: Singapore Health Services PTE LTD.; National University of Singapore
- Inventors: Stuart Alexander Cook; Sebastian Schaefer
- Web page: https://patentgrep.com/patent/US11078269B2

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/5431: {IL-11}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6869: {Interleukin}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- G01N 2333/7155: for interleukins [IL]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

IL-11Rα antibodies are disclosed. Also disclosed are compositions comprising the IL-11Rα antibodies, and methods using the IL-11Rα antibodies.

## Claims

### Claim 1

An antibody or antigen binding fragment, which is capable of binding to IL-11Rα, comprising a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence comprises the following CDRS:
(SEQ ID NO: 33)
LC-CDR1: QSISNN;
(SEQ ID NO: 34)
LC-CDR2: YAS;
and
(SEQ ID NO: 35)
LC-CDR3: QQRYSWPLT,
or a variant comprising 1 amino acid substitution in the sequence QQRYSWPLT (SEQ ID NO: 35); and
the heavy chain variable region sequence comprises the following CDRs:
(SEQ ID NO: 60)
HC-CDR1: GYTFTNYW;
(SEQ ID NO: 61)
HC-CDR2: IGPSDSKT;
and
(SEQ ID NO: 62)
HC-CDR3: ARGDYVLFTY.

### Claim 2 (depends on 1)

The antibody or antigen binding fragment according to claim 1, wherein:
the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO: 7, and
the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16.

### Claim 3 (depends on 1)

The antibody or antigen binding fragment according to claim 1, wherein the light chain variable region sequence comprises the following CDRs:
(SEQ ID NO: 33)
i) LC-CDR1: QSISNN;
(SEQ ID NO: 34)
ii) LC-CDR2: YAS;
and
(SEQ ID NO: 35)
iii) LC-CDR3: QQRYSWPLT;
and wherein the heavy chain variable region sequence comprises the following CDRs:
(SEQ ID NO: 60)
iv) HC-CDR1: GYTFTNYW;
(SEQ ID NO: 61)
v) HC-CDR2: IGPSDSKT;
and
(SEQ ID NO: 62)
vi) HC-CDR3: ARGDYVLFTY.

### Claim 4 (depends on 1)

The antibody or antigen binding fragment according to claim 1, which is capable of inhibiting IL-11 trans signalling.

### Claim 5 (depends on 1)

The antibody or antigen binding fragment according to claim 1, wherein the antibody or antigen binding fragment is a humanised antibody or antigen binding fragment.

### Claim 6 (depends on 1)

The antibody or antigen binding fragment according claim 1, conjugated to a drug moiety or a detectable moiety.

### Claim 7 (depends on 1)

A method for producing an antibody or antigen binding fragment according to claim 1, comprising culturing a cell comprising a nucleic acid or vector encoding the antibody or antigen binding fragment according to claim 1 under conditions suitable for the expression of the antibody or antigen binding fragment.

### Claim 8 (depends on 7)

The method of claim 7, further comprising isolating the antibody or antigen binding fragment from the cell, thereby producing an isolated antibody or antigen binding fragment.

### Claim 9 (depends on 8)

The method of claim 8, further comprising mixing the isolated antibody or antigen binding fragment with a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.

### Claim 10

A method of treating fibrosis or a disease/disorder characterised by fibrosis, comprising administering an antibody or antigen binding fragment to a subject suffering from fibrosis or a disease/disorder characterised by fibrosis, wherein the antibody or antigen binding fragment is capable of binding to IL-11Rα, and comprises a light chain variable region sequence and a heavy chain variable region sequence, wherein:
the light chain variable region sequence comprises the following CDRs:
(SEQ ID NO: 33)
LC-CDR1: QSISNN;
(SEQ ID NO: 34)
LC-CDR2: YAS;
and
(SEQ ID NO: 35)
LC-CDR3: QQRYSWPLT,
or a variant comprising 1 amino acid substitution in the sequence QQRYSWPLT (SEQ ID NO: 35); and
the heavy chain variable region sequence comprises the following CDRs:
(SEQ ID NO: 60)
HC-CDR1: GYTFTNYW;
(SEQ ID NO: 61)
HC-CDR2: IGPSDSKT;
and
(SEQ ID NO: 62)
HC-CDR3: ARGDYVLFTY.

### Claim 11 (depends on 10)

The method according to claim 10, wherein:
the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO: 7, and
the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO: 16.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the light chain variable region sequence comprises the following CDRs:
(SEQ ID NO: 33)
i) LC-CDR1: QSISNN;
(SEQ ID NO: 34)
ii) LC-CDR2: YAS;
and
(SEQ ID NO: 35)
iii) LC-CDR3: QQRYSWPLT;
and wherein the heavy chain variable region sequence comprises the following CDRs:
(SEQ ID NO: 60)
iv) HC-CDR1: GYTFTNYW;
(SEQ ID NO: 61)
v) HC-CDR2: IGPSDSKT;
and
(SEQ ID NO: 62)
vi) HC-CDR3: ARGDYVLFTY.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the antibody or antigen binding fragment is capable of inhibiting IL-11 trans signalling.

### Claim 14 (depends on 10)

The method according to claim 10, wherein the antibody or antigen binding fragment is a humanised antibody or antigen binding fragment.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the antibody or antigen binding fragment is conjugated to a drug moiety or a detectable moiety.